LIVE
Novel and early-stage research peptides with unresolved classification or limited preclinical data. Not approved for any use.
This category holds peptides with unresolved classification, early-stage preclinical status, or a mechanism of action that does not map cleanly to the other nine classes.
PNC-27 is the sole current member — a 32-amino-acid chimeric peptide combining a p53-derived HDM2-binding domain with a membrane-resident peptide (MRP) transduction sequence. Preclinical studies report selective cytotoxicity toward transformed cells via membrane pore formation, with apparent sparing of non-transformed cells. It has not progressed to human phase-I trials and is not FDA-approved for any indication.
Listings in this category exist for catalog completeness, so vendors selling unusual or boundary compounds can be price-compared without those compounds contaminating better-established classes. Peptides placed here are explicitly not recommended for any human use.